Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-07-05
2011-07-05
Shiao, Rei-tsang (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S255010
Reexamination Certificate
active
07973041
ABSTRACT:
The present invention provides compounds of the formula:its enantiomers, diastereomers, racemic mixtures thereof, prodrugs, crystalline forms, non-crystalline forms, amorphous forms thereof, solvates thereof, metabolites thereof, and pharmaceutically acceptable salts, wherein the ring A substituent groups are fully defined in the following disclosure. The compounds of formula are inhibitors of metalloproteases such as matrix metalloproteases and sheddases, and are useful in treating diseases such as rheumatoid arthritis, psoriasis, neoplastic diseases, allergies and all those diseases wherein inhibition of MMPs is desirable.
REFERENCES:
patent: 5872152 (1999-02-01), Brown et al.
patent: 5892112 (1999-04-01), Levy et al.
patent: 5968795 (1999-10-01), Dixon et al.
patent: 6268379 (2001-07-01), Xue et al.
patent: 6436960 (2002-08-01), Shin et al.
patent: 6500847 (2002-12-01), Van Zandt et al.
patent: 7491724 (2009-02-01), Li et al.
patent: 2004/0247602 (2004-12-01), Friedman et al.
patent: 2004/0259896 (2004-12-01), Yao et al.
patent: 2005/0250789 (2005-11-01), Burns et al.
patent: 2007/0117809 (2007-05-01), Fridman
patent: 2007/0280943 (2007-12-01), Friedman et al.
patent: WO 99/65867 (1999-06-01), None
patent: WO 99/58531 (1999-11-01), None
patent: WO 01/70673 (2001-09-01), None
patent: WO 02/055491 (2002-07-01), None
Black, R.A.,Int. J. Biochem. Cell Biolvol. 34, pp. 1-5, 2002.
Bode, W. et al.,Adv. Exp. Med Biol, vol. 389,, pp. 1-11, 1996.
Bohm et al.,Arthritis&Rheumatism, vol. 42(9), pp. 1946-1950, 1999.
Burns, D. M. et al,, “Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P′1permutations,”Bioorg. Med. Chem. Lett. , 2008, 18, 560-564.
Bursavich, M. G. and Rich, D. H. Org. Lett. 2001, 3, 2625.
Chem. Abs. 132:49888 (abstracting Xue, et al. WO 99/65867) (1999).
Codony-Servat et al., 1999,Cancer Res, vol. 59, pp. 1196-1201.
Combs et al., “N-Arylation of Primary and Secondary Aliphatic Amines on Solid Supports”,J. Comb. Chem. 2002, 4, pp. 179.
Dankwardt, S. M., et al.,Tetrahedron Lett. 1995, 36, 4923.
Fridman, J.S. et al., “Selective Inhibition of ADAM Metalloproteases as a Novel Approach for Modulating ErbB pathways in Cancer”,Clin. Canc. Res., 2007, 13(6), 1892-1901.
Gais et al.,J. Org. Chem. 1989, vol. 54, p. 5115.
Herren et al., 1997,FASEB J., vol. 11, pp. 173-180.
Hooper, 1994,FEBS Lett, vol. 354, pp. 1-6.
Horiuchi et al., 2003,Mol Cell Biol, vol. 23, pp. 5614-5624.
Jacobsen,Acc. Chem. Res. 2000, vol. 33, p. 421.
Joucla et al.,Chem. Commun. 1985, p. 1566.
Kaushal et al., 2000,J Clin Invest, vol. 105, pp. 1335-1337.
Levin et al.,Syn. Comm. 1982, vol. 12, p. 989.
Louie, J; Hartwig, J. F. Tetrahedron Lett. 1995, 36, 3609.
Liu, P.C.C. et al., “Identification of ADAM10 AS a Major Source of HER-2 Ectodomain Sheddase Activity in HER2 Overexpressing Breast Cancer Cells”,Cancer Biol. Ther., 2006, 5:6, 657-664.
Liu, X. et al., “Selective Inhibition of ADAM Metalloproteases blocks HER-2 Extracellular Domain (ECD) Cleavage and Potentiates the Anti-Tumor Effects of Trastuzumab”,Cancer Biol. Ther., 2006,.5:6, 648-655.
Mayer et al., 2002,Inflamm Res, vol. 51, pp. 85-90.
Mishani, E. et. al. Tetrahedron Lett. 1996, 37, 319.
Moscatelli et al., 1988,Biochim Biophys Acta, vol. 948, pp. 67-85.
Moss et al., 2001,Drug Discov Today, vol. 6, pp. 417-426.
Moss et al., 2002,Essays Biochem, vol. 38, pp. 141-153.
Muller, A.J. and Scherle, P.A., “Targeting the Mechanisms of Tumoral Immune Tolerance with Small-molecule Inhibitors”Nature Rev. Cancer, 2006, 6, 613-626.
Novak et al., 2001,Curr Opin Immunol, vol. 13, pp. 721-726.
Parks, 2002,J Clin Invest., vol. 110, pp. 613-614.
Rio et al., 2000,J Biol Chem, vol. 275, pp. 10379-10387.
Seals et al., 2003,Genes and Development, vol. 17, pp. 7-30.
Slamon et al., 1987,Science, vol. 235, pp. 177-182.
Stocker et al., 1995,Curr Opin Struct Biol, vol. 5, pp. 383-390.
Tang, 2001,Int J. Biochem. Cell Biol, vol. 33, pp. 33-44.
B.M. Trost, and I. Fleming, “Comprehensive Organic Synthesis”, Eds. Pergamon, 1991, vol. 8, Part 1.2, P25, Part 3.1, p. 729.
Wang et al.,J. Org Chem. 1992, vol. 57, p. 6101.
Winyard et al., 1991,FEBS Letts, vol. 279, pp. 91-94.
Wolfsberg, et al, J. Cell Bio. vol. 131, pp. 275-278 Oct. 25, 1995.
Xue et al.,J. Org. Chem. 2002, vol. 67, p. 865.
Yao, W. et al., “Discovery of Potent, Selective, and Orally Active Human Epidermal Growth Factor Receptor-2 Sheddase Inhibitor of the Treatment of Cancer,”J. Med. Chem. 2007, 50, 603-606.
Yao, W., et al., “Design and identification of selective HER-2 sheddase inhibitors via P1′ manipulation and unconventional P2′ perturbations to induce a molecular metamorphosis”,Bioorg. Med. Chem. Lett. , 2008, 18, 159-163.
Yarden et al., 2001,Nature Reviews, vol. 2, pp. 127-137.
Zhou, Bin-Bing S. et al., “Targeting ADAM-mediated Ligand Cleavage to Inhibit HER3 and EGFR Pathways in Non-small Cell Lung Cancer”,Cancer Cell, 2006, 10, 39-50.
Zhuo, J. et al., “Asymmetric Synthesis of Conformationally Constrained trans-2,3-Piperidine-Dicarboxylic Acid Derivatives”,SYNLETT, 2007, No. 3, 460-464.
Friedman et al; “Clinical benefit of INCB7839, a potent and selective inhibitor of ADAM10 and ADAM17, in combination with trastuzumab in metastatic HER2 positive breast cancer patients.” Abstract and slide presentation from the 32ndAnnual San Antonio Breast Cancer Symposium; Dec. 9-13, 2009, San Antonio, Texas; Incyte Corporation; 20 pages.
Liu et al; “Selective Inhibition of ADAM Metalloproteases Blocks HER-2 Extracellular Domain (ECD) Cleavage and Potentiates the Anti-Tumor Effects of Trastuzumab”Cancer Biology&Therapy, 5:6; 648-656; Jun. 2006.
Newton et al; “Clinical Benefit of INCB7839, A Potent and Selective ADAM Inhibitor, in Combination With Trastuzumab in Metastatic HER2+Breast Cancer Patients.” Abstract and slide presentation from the American Society of Clinical Oncology (Jun. 4-8, 2010), 10 pages.
Extended European Search Report for Application No. 10182170.0, dated Nov. 22, 2010 (5 pages).
Burns David M.
Jalluri Ravi Kumar
Li Yun-Long
Yao Wenqing
Zhuo Jincong
Fish & Richardson P.C.
Incyte Corporation
Shiao Rei-tsang
LandOfFree
Substituted cyclic hydroxamates as inhibitors of matrix... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted cyclic hydroxamates as inhibitors of matrix..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted cyclic hydroxamates as inhibitors of matrix... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2738831